Business Daily from THE HINDU group of publications
Tuesday, Nov 03, 2009
ePaper | Mobile/PDA Version | Audio | Blogs
Business Daily from THE HINDU group of publications Tuesday, Nov 03, 2009 ePaper | Mobile/PDA Version | Audio | Blogs |
|
|
|
|
|
Corporate
-
Announcements Marketing - New Products & Services Web Extras - Pharmaceuticals Cadila launches new TB drug Our Bureau Ahmedabad, Nov. 2 Cadila Pharmaceuticals Ltd has launched Risorine, an anti-tubercular drug, which is expected to increase the turnover of the company by 30-40 per cent, according to an official. Priced at Rs 25 for six capsules, Risorine is 23 per cent cheaper than the other medicines available in the market for the treatment of tuberculosis, said Dr Naresh R. Patel, a TB specialist. Risorine is the first boosted rifampicin containing fixed dose combination, but is not a single-dose remedy, he said. It shows an improvement of 7 per cent in the recovery rate and if administered a course of six months, it increases the chances of cure, decreasing chances of a relapse, according to him. Risorine is the outcome of a public-private partnership between the Indian Institute of Integrative Medicine, Jammu, an institute of Council of Scientific and Industrial Research, and Cadila Pharma. It contains piperine, which inhibits auto induction and maintains same level throughout therapy. It also allows use of lower dosage of rifampicin, 200 mg instead of 450 mg and has lower gastro-intestinal side effects, according to him. Cadila loses trademark case against Wallace Pharma Cadila expects Rs 100 cr revenue from Polycap More Stories on : Announcements | New Products & Services | Pharmaceuticals
Article E-Mail :: Comment :: Syndication :: Printer Friendly Page
|
|
The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription Group Sites: The Hindu | The Hindu ePaper | Business Line | Business Line ePaper | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |
Copyright © 2009, The
Hindu Business Line. Republication or redissemination of the contents of
this screen are expressly prohibited without the written consent of
The Hindu Business Line
|